【sauce for trader joe's pumpkin ravioli】Psyched: The First Psychedelics ETF, Beckley Raises $19M, 3 Companies Go Public
Thesauce for trader joe's pumpkin ravioli Psychedelics Sector Might Soon Get Its First ETF
Financial services company
Horizons ETFs Management
filed documents with the Ontario Securities Commission for a psychedelics ETF, which is expected to go live on Jan. 15.
The ‘Horizons Psychedelic Stock Index ETF’ would become the first ETF offering dedicated exposure to the psychedelics sector.
The firm, which manages the
Horizons Marijuana Life Sciences Index ETF
(TSX: HMMJ) (OTC:
HMLSF
) among over 93 separate ETFs, has yet to make a public announcement on the launch.
Psilocybin Alpha published a review
of the filings, which state that the ETF intends to invest in companies from the psychedelics industry engaged in legal activities with psychedelic drugs.
The ETF is expected to list under the symbol ‘PSYK’ on Canada’s NEO Exchange. It will be a passive ETF, following the North American Psychedelic Stock Index from Solactive, a German financial indices provider.
Beckley Psytech Raises $19M For 5-MeO-DMT Research
Beckley Psytech
, the for-profit arm of the
Beckley Foundation
, raised £14 million (approximately US$19 million) in equity funding.
The proceeds will be used in part to finance a drug development pipeline for 5-MeO-DMT, a psychedelic compound naturally produced by the Sonoran Desert Toad, which has chemical similarities to DMT. The company is in preparations to commence clinical trials on 5-MeO-DMT, according to
Business Leader.
The Beckley Foundation is a UK-based think tank and UN-accredited NGO that has been leading research on psychedelics since the late 1990s.
The organization, led by Amanda Feilding, Countess of Wemyss, developed a for profit branch in 2019 in order to navigate the expensive business of clinical research.
The company raised £3 million in May of 2020. This round’s new investors include Noetic Psychedelic Fund LP, a venture fund focused on psychedelics, and Bail Capital.
3 New Psychedelics Companies Go Public
Three companies recently announced go-public dates, adding to the
more than 20 psychedelics companies
that hit the public markets in 2020.
Mindset Pharma
began listing in the Canadian Securities Exchange on Dec. 23 under the symbol ‘MSET.’ The Toronto-based company is putting together a library of intellectual property on psychedelic compounds designed to address chronic neuro-psychiatric disorders.
The company has already synthesized 50 compounds and filed 4 patents on novel chemical structures and synthesis processes.
NeonMind Biosciences
, a partially-owned subsidiary of
Better Plant Sciences
(CSE: PLNT) (OTCQB:
VEGGF
), announced that it has received approval to list on the CSE on Jan. 4, under the symbol ‘NEON.’
Story continues
Better Plant owns over 33 million common shares in NeonMind. In November 2020, NeonMind received Health Canada approval to begin pre-clinical trials on the use of psilocybin for food cravings in the context of obesity. The company has also launched a line of non-psychedelic
functional mushroom
dietary supplements.
Novamind
, a Toronto-based mental health company focused on providing access to legal psychedelic therapies, is going public on the CSE on Jan. 5 under the symbol ‘NM.’
The company is developing a three tier business plan through a network of psychedelics-assisted therapy clinics, psychedelics retreats and a clinical research division, focused on providing research infrastructure to other companies in and outside the sector.
The Milestone Round
Psyched Wellness
(CSE: PSYC) (OTCQB:
DCNPF
) announced the launch of its pre-clinical trials on Amanita Muscaria, a type of legal psychoactive mushroom. The first section of the study will focus on analyzing the mushroom’s maximum tolerated dose. On Wednesday, the company also announced starting research on Muscimol, Amanita’s main psychoactive ingredient, for various psychiatric conditions.
Core One Labs
(CSE:COOL), (OTC:
CLABF
) announced the purchase of
Vocan Biotechnologies
, a Canadian-based genetic engineering and biosynthesis research firm, through an all-stock transaction. Vocan is developing a proprietary
production method to biosynthesize psilocybin
.
Revive Therapeutics
(CSE: RVV) (PINK:
RVVTF
) announced a letter of intent to acquire full rights to
PharmaTher
’s intellectual property on psilocybin. These include PharmaTher’s pre-clinical research into traumatic brain injury and stroke, and provisional patent applications on the use of psilocybin for various ailments.
PharmaTher is a wholly-owned subsidiary of
Newscope Capital Corporation
(PINK:
PHRRF
).
See more from Benzinga
Click here for options trades from Benzinga
2020 Was The Year of Psychedelics — Here's Why
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
View comments
-
US Test Preparation Market 2020-2024 - Increasing Use of Analytical Tools and Emphasis of Online Test Preparation Modes Driving Market DemandColombia's Cano Limon pipeline bombed for 9th time in 2019Sensex, Nifty gain, 10-year yields spike after budgetWill Nordstrom's Growth Efforts Cushion the Stock in 2019?Voya: 3Q Earnings SnapshotBRIEF-Shanghai Guangdian Electric's Board Elects Zhao Shuwen As ChairwomanHere is Why Growth Investors Should Buy Broadcom Inc. (AVGO) NowWhat You Need To Know Before Investing In Arena REIT (ASX:ARF)Key Things To Watch Out For If You Are After Richardson Electronics, Ltd.'s (NASDAQ:RELL) 6.7% DividendBRIEF-Hebei Yangyuan ZhiHui Beverage, Units Receive Government Supporting Fund Of 239.5 Mln Yuan
下一篇:GBP/USD Daily Forecast – Consolidation Around 1.2400 Continues
- ·Are Options Traders Betting on a Big Move in Penn National (PENN) Stock?
- ·Why Rogers Sugar Inc. (TSE:RSI) Looks Like A Quality Company
- ·BRIEF-Beijing Thunisoft Gets Regulatory Approval For Share Private Placement
- ·Could The Gladstone Commercial Corporation (NASDAQ:GOOD) Ownership Structure Tell Us Something Useful?
- ·Did Business Growth Power Ling Yui Holdings's (HKG:784) Share Price Gain of 222%?
- ·Is Best Buy Co., Inc.’s (NYSE:BBY) ROE Of 36% Impressive?
- ·American Assets Trust Inc (AAT) Chairman, CEO & President Ernest S Rady Bought $430,471 of ...
- ·Excerpts of high court campaign finance opinions
- ·What Cineworld Group plc’s (LON:CINE) ROE Can Tell Us
- ·Indian Oil says Iran may still invest in Chennai Petroleum expansion
- ·Regional observers endorse Congo's election - with caveats
- ·Those who invested in Anglo Asian Mining (LON:AAZ) five years ago are up 437%
- ·China's Xi Visits Wuhan, Says Coronavirus Outbreak 'Basically Curbed'
- ·Spirit AeroSystems revenue rises 7 pct
- ·Marvel’s Luke Cage Gets Premiere Date
- ·What Should Investors Know About TKH Group N.V.’s (AMS:TWEKA) Growth?
- ·Asian Shares Lower as US-China Tensions Weigh on Investor Sentiment
- ·Has The Progressive (PGR) Outpaced Other Finance Stocks This Year?
- ·BRIEF-State Energy Group International Assets Holdings Says Au Yeung Ho Yin Resigns As CFO
- ·What You Must Know About Total Brain Limited’s (ASX:TTB) Financial Strength
- ·Founder Alexander Reilley Just Bought 10.0% More Shares In Loungers plc (LON:LGRS)
- ·Axiom Prepaid Holdings Caps Off Banner Year with a Prestigious Accolade for Its CEO
- ·Adamis Has 'Favorable' Pipeline Setup, Says Bullish Raymond James
- ·VNM: Question & Answer
- ·Top Analyst Reports for Apple, Verizon & PayPal
- ·The Big Bang Theory adds Walton Goggins, Beth Behrs
- ·Should Value Investors Consider Dycom (DY) Stock Now?
- ·Dover Corporation (NYSE:DOV): What’s The Analyst Consensus Outlook?
- ·BRIEF-Kong Sun Holdings Says Expects Unaudited Consol Profit Attributable To Owners Of Co To Decrease
- ·Tom Brady Announces NFL Retirement: 'This Is Difficult for Me... '
- ·Deutsche (DB) Ratings Affirmed by Moody's, Outlook Upgraded
- ·BRIEF-Sunshine 100 China Posts January Contracted Sales Of RMB299 Mln
- ·Is B2Gold (TSE:BTO) A Risky Investment?
- ·Colombia's Cano Limon pipeline bombed for 9th time in 2019
- ·BRIEF-Wangfujing Group, BTG Hotels' Chairman Passed Away Due To Illness
- ·How Much Are Cranswick plc (LON:CWK) Insiders Taking Off The Table?